Treatment Arms Were Balanced in the Phase 3 NOVA Study of ZEJULA1
Baseline Patient Characteristsics Across Cohorts1
*One patient received one line of prior therapy.
BRCA, breast cancer susceptibility gene; ECOG, Eastern Cooperative Oncology Group; gBRCAmut, germline BRCA mutated; min, minimum; max, maximum; non-gBRCAmut, not germline BRCA mutated.
Reference: 1. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.
See the clinical rigor behind the pivotal trial design for ZEJULA
See PFS in HRDpos and HRDneg patient subgroups
Learn about the safety and tolerability of ZEJULA
See the pivotal phase 3 trial publication